A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score

Ho Young Yhim, Yong Park, Yeon Hee Han, Sungeun Kim, Sae Ryung Kang, Joon Ho Moon, Ju Hye Jeong, Ho Jin Shin, Keunyoung Kim, Yoon Seok Choi, Kunho Kim, Min Kyoung Kim, Eunjung Kong, Dae Sik Kim, Jae Seon Eo, Ji Hyun Lee, Do Young Kang, Won Sik Lee, Seok Mo Lee, Young Rok DoJun Soo Ham, Seok Jin Kim, Won Seog Kim, Joon Young Choi, Deok Hwan Yang, Jae Yong Kwak

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: The aim of this study was to establish a risk-stratification model integrating posttreatment metabolic response using the Deauville score and the pretreatment National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI) in nodal PTCLs. Methods: We retrospectively analysed 326 patients with newly diagnosed nodal PTCLs between January 2005 and June 2016 and both baseline and posttreatment PET/CT data. The final model was validated using an independent prospective cohort of 79 patients. Results: Posttreatment Deauville score (1/2, 3, and 4/5) and the NCCN-IPI (low, low-intermediate, high-intermediate, and high) were independently associated with progression-free survival: for the Deauville score, the hazard ratios (HRs) were 1.00 vs. 2.16 (95% CI 1.47–3.18) vs. 7.86 (5.66–10.92), P < 0.001; and for the NCCN-IPI, the HRs were 1.00 vs. 2.31 (95% CI 1.20–4.41) vs. 4.42 (2.36–8.26) vs. 7.09 (3.57–14.06), P < 0.001. Based on these results, we developed a simplified three-group risk model comprising a low-risk group (low or low-intermediate NCCN-IPI with a posttreatment Deauville score of 1 or 2, or low NCCN-IPI with a Deauville score of 3), a high-risk group (high or high-intermediate NCCN-IPI with a Deauville score of 1/2 or 3, or low-intermediate NCCN-IPI with a Deauville score of 3), and a treatment failure group (Deauville score 4 or 5). This model was significantly associated with progression-free survival (5-year, 70.3%, 31.4%, and 4.7%; P < 0.001) and overall survival (5-year, 82.1%, 45.5%, and 14.7%; P < 0.001). Similar associations were also observed in the independent validation cohort. Conclusion: The risk-stratification model integrating posttreatment Deauville score and pretreatment NCCN-IPI is a powerful tool for predicting treatment failure in patients with nodal PTCLs.

Original languageEnglish
Pages (from-to)2274-2284
Number of pages11
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume45
Issue number13
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Peripheral T-Cell Lymphoma
Neoplasms
Treatment Failure
Disease-Free Survival
Survival

Keywords

  • International prognostic index
  • Peripheral T-cell lymphoma
  • PET/CT
  • Prognosis
  • Treatment

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score. / Yhim, Ho Young; Park, Yong; Han, Yeon Hee; Kim, Sungeun; Kang, Sae Ryung; Moon, Joon Ho; Jeong, Ju Hye; Shin, Ho Jin; Kim, Keunyoung; Choi, Yoon Seok; Kim, Kunho; Kim, Min Kyoung; Kong, Eunjung; Kim, Dae Sik; Eo, Jae Seon; Lee, Ji Hyun; Kang, Do Young; Lee, Won Sik; Lee, Seok Mo; Do, Young Rok; Ham, Jun Soo; Kim, Seok Jin; Kim, Won Seog; Choi, Joon Young; Yang, Deok Hwan; Kwak, Jae Yong.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, No. 13, 01.12.2018, p. 2274-2284.

Research output: Contribution to journalArticle

Yhim, HY, Park, Y, Han, YH, Kim, S, Kang, SR, Moon, JH, Jeong, JH, Shin, HJ, Kim, K, Choi, YS, Kim, K, Kim, MK, Kong, E, Kim, DS, Eo, JS, Lee, JH, Kang, DY, Lee, WS, Lee, SM, Do, YR, Ham, JS, Kim, SJ, Kim, WS, Choi, JY, Yang, DH & Kwak, JY 2018, 'A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score', European Journal of Nuclear Medicine and Molecular Imaging, vol. 45, no. 13, pp. 2274-2284. https://doi.org/10.1007/s00259-018-4093-1
Yhim, Ho Young ; Park, Yong ; Han, Yeon Hee ; Kim, Sungeun ; Kang, Sae Ryung ; Moon, Joon Ho ; Jeong, Ju Hye ; Shin, Ho Jin ; Kim, Keunyoung ; Choi, Yoon Seok ; Kim, Kunho ; Kim, Min Kyoung ; Kong, Eunjung ; Kim, Dae Sik ; Eo, Jae Seon ; Lee, Ji Hyun ; Kang, Do Young ; Lee, Won Sik ; Lee, Seok Mo ; Do, Young Rok ; Ham, Jun Soo ; Kim, Seok Jin ; Kim, Won Seog ; Choi, Joon Young ; Yang, Deok Hwan ; Kwak, Jae Yong. / A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score. In: European Journal of Nuclear Medicine and Molecular Imaging. 2018 ; Vol. 45, No. 13. pp. 2274-2284.
@article{e12167323f194c76aa99c46a03d7979f,
title = "A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score",
abstract = "Purpose: The aim of this study was to establish a risk-stratification model integrating posttreatment metabolic response using the Deauville score and the pretreatment National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI) in nodal PTCLs. Methods: We retrospectively analysed 326 patients with newly diagnosed nodal PTCLs between January 2005 and June 2016 and both baseline and posttreatment PET/CT data. The final model was validated using an independent prospective cohort of 79 patients. Results: Posttreatment Deauville score (1/2, 3, and 4/5) and the NCCN-IPI (low, low-intermediate, high-intermediate, and high) were independently associated with progression-free survival: for the Deauville score, the hazard ratios (HRs) were 1.00 vs. 2.16 (95{\%} CI 1.47–3.18) vs. 7.86 (5.66–10.92), P < 0.001; and for the NCCN-IPI, the HRs were 1.00 vs. 2.31 (95{\%} CI 1.20–4.41) vs. 4.42 (2.36–8.26) vs. 7.09 (3.57–14.06), P < 0.001. Based on these results, we developed a simplified three-group risk model comprising a low-risk group (low or low-intermediate NCCN-IPI with a posttreatment Deauville score of 1 or 2, or low NCCN-IPI with a Deauville score of 3), a high-risk group (high or high-intermediate NCCN-IPI with a Deauville score of 1/2 or 3, or low-intermediate NCCN-IPI with a Deauville score of 3), and a treatment failure group (Deauville score 4 or 5). This model was significantly associated with progression-free survival (5-year, 70.3{\%}, 31.4{\%}, and 4.7{\%}; P < 0.001) and overall survival (5-year, 82.1{\%}, 45.5{\%}, and 14.7{\%}; P < 0.001). Similar associations were also observed in the independent validation cohort. Conclusion: The risk-stratification model integrating posttreatment Deauville score and pretreatment NCCN-IPI is a powerful tool for predicting treatment failure in patients with nodal PTCLs.",
keywords = "International prognostic index, Peripheral T-cell lymphoma, PET/CT, Prognosis, Treatment",
author = "Yhim, {Ho Young} and Yong Park and Han, {Yeon Hee} and Sungeun Kim and Kang, {Sae Ryung} and Moon, {Joon Ho} and Jeong, {Ju Hye} and Shin, {Ho Jin} and Keunyoung Kim and Choi, {Yoon Seok} and Kunho Kim and Kim, {Min Kyoung} and Eunjung Kong and Kim, {Dae Sik} and Eo, {Jae Seon} and Lee, {Ji Hyun} and Kang, {Do Young} and Lee, {Won Sik} and Lee, {Seok Mo} and Do, {Young Rok} and Ham, {Jun Soo} and Kim, {Seok Jin} and Kim, {Won Seog} and Choi, {Joon Young} and Yang, {Deok Hwan} and Kwak, {Jae Yong}",
year = "2018",
month = "12",
day = "1",
doi = "10.1007/s00259-018-4093-1",
language = "English",
volume = "45",
pages = "2274--2284",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "13",

}

TY - JOUR

T1 - A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score

AU - Yhim, Ho Young

AU - Park, Yong

AU - Han, Yeon Hee

AU - Kim, Sungeun

AU - Kang, Sae Ryung

AU - Moon, Joon Ho

AU - Jeong, Ju Hye

AU - Shin, Ho Jin

AU - Kim, Keunyoung

AU - Choi, Yoon Seok

AU - Kim, Kunho

AU - Kim, Min Kyoung

AU - Kong, Eunjung

AU - Kim, Dae Sik

AU - Eo, Jae Seon

AU - Lee, Ji Hyun

AU - Kang, Do Young

AU - Lee, Won Sik

AU - Lee, Seok Mo

AU - Do, Young Rok

AU - Ham, Jun Soo

AU - Kim, Seok Jin

AU - Kim, Won Seog

AU - Choi, Joon Young

AU - Yang, Deok Hwan

AU - Kwak, Jae Yong

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Purpose: The aim of this study was to establish a risk-stratification model integrating posttreatment metabolic response using the Deauville score and the pretreatment National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI) in nodal PTCLs. Methods: We retrospectively analysed 326 patients with newly diagnosed nodal PTCLs between January 2005 and June 2016 and both baseline and posttreatment PET/CT data. The final model was validated using an independent prospective cohort of 79 patients. Results: Posttreatment Deauville score (1/2, 3, and 4/5) and the NCCN-IPI (low, low-intermediate, high-intermediate, and high) were independently associated with progression-free survival: for the Deauville score, the hazard ratios (HRs) were 1.00 vs. 2.16 (95% CI 1.47–3.18) vs. 7.86 (5.66–10.92), P < 0.001; and for the NCCN-IPI, the HRs were 1.00 vs. 2.31 (95% CI 1.20–4.41) vs. 4.42 (2.36–8.26) vs. 7.09 (3.57–14.06), P < 0.001. Based on these results, we developed a simplified three-group risk model comprising a low-risk group (low or low-intermediate NCCN-IPI with a posttreatment Deauville score of 1 or 2, or low NCCN-IPI with a Deauville score of 3), a high-risk group (high or high-intermediate NCCN-IPI with a Deauville score of 1/2 or 3, or low-intermediate NCCN-IPI with a Deauville score of 3), and a treatment failure group (Deauville score 4 or 5). This model was significantly associated with progression-free survival (5-year, 70.3%, 31.4%, and 4.7%; P < 0.001) and overall survival (5-year, 82.1%, 45.5%, and 14.7%; P < 0.001). Similar associations were also observed in the independent validation cohort. Conclusion: The risk-stratification model integrating posttreatment Deauville score and pretreatment NCCN-IPI is a powerful tool for predicting treatment failure in patients with nodal PTCLs.

AB - Purpose: The aim of this study was to establish a risk-stratification model integrating posttreatment metabolic response using the Deauville score and the pretreatment National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI) in nodal PTCLs. Methods: We retrospectively analysed 326 patients with newly diagnosed nodal PTCLs between January 2005 and June 2016 and both baseline and posttreatment PET/CT data. The final model was validated using an independent prospective cohort of 79 patients. Results: Posttreatment Deauville score (1/2, 3, and 4/5) and the NCCN-IPI (low, low-intermediate, high-intermediate, and high) were independently associated with progression-free survival: for the Deauville score, the hazard ratios (HRs) were 1.00 vs. 2.16 (95% CI 1.47–3.18) vs. 7.86 (5.66–10.92), P < 0.001; and for the NCCN-IPI, the HRs were 1.00 vs. 2.31 (95% CI 1.20–4.41) vs. 4.42 (2.36–8.26) vs. 7.09 (3.57–14.06), P < 0.001. Based on these results, we developed a simplified three-group risk model comprising a low-risk group (low or low-intermediate NCCN-IPI with a posttreatment Deauville score of 1 or 2, or low NCCN-IPI with a Deauville score of 3), a high-risk group (high or high-intermediate NCCN-IPI with a Deauville score of 1/2 or 3, or low-intermediate NCCN-IPI with a Deauville score of 3), and a treatment failure group (Deauville score 4 or 5). This model was significantly associated with progression-free survival (5-year, 70.3%, 31.4%, and 4.7%; P < 0.001) and overall survival (5-year, 82.1%, 45.5%, and 14.7%; P < 0.001). Similar associations were also observed in the independent validation cohort. Conclusion: The risk-stratification model integrating posttreatment Deauville score and pretreatment NCCN-IPI is a powerful tool for predicting treatment failure in patients with nodal PTCLs.

KW - International prognostic index

KW - Peripheral T-cell lymphoma

KW - PET/CT

KW - Prognosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85050828172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050828172&partnerID=8YFLogxK

U2 - 10.1007/s00259-018-4093-1

DO - 10.1007/s00259-018-4093-1

M3 - Article

C2 - 30056546

AN - SCOPUS:85050828172

VL - 45

SP - 2274

EP - 2284

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 13

ER -